Exact Mass: 254.9621
Exact Mass Matches: 254.9621
Found 217 metabolites which its exact mass value is equals to given mass value 254.9621,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Garlon
CONFIDENCE standard compound; INTERNAL_ID 59; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4237; ORIGINAL_PRECURSOR_SCAN_NO 4232 CONFIDENCE standard compound; INTERNAL_ID 59; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4245; ORIGINAL_PRECURSOR_SCAN_NO 4242 CONFIDENCE standard compound; INTERNAL_ID 59; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4244; ORIGINAL_PRECURSOR_SCAN_NO 4241 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2946 EAWAG_UCHEM_ID 2946; CONFIDENCE standard compound D010575 - Pesticides > D006540 - Herbicides D016573 - Agrochemicals
lamotrigine
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators CONFIDENCE standard compound; INTERNAL_ID 1528 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 86 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2676
Lamotrigine
Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. The exact way lamotrigine works is unknown. [Wikipedia] D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
Anagrelide
Anagrelide is only found in individuals that have used or taken this drug. It is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. [Wikipedia]The mechanism by which anagrelide reduces blood platelet count is still under investigation. Studies in patients support a hypothesis of dose-related reduction in platelet production resulting from a decrease in megakaryocyte hypermaturation. In blood withdrawn from normal volunteers treated with anagrelide, a disruption was found in the postmitotic phase of megakaryocyte development and a reduction in megakaryocyte size and ploidy. At therapeutic doses, anagrelide does not produce significant changes in white cell counts or coagulation parameters, and may have a small, but clinically insignificant effect on red cell parameters. Anagrelide inhibits cyclic AMP phosphodiesterase III (PDEIII). PDEIII inhibitors can also inhibit platelet aggregation. However, significant inhibition of platelet aggregation is observed only at doses of anagrelide higher than those required to reduce platelet count. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
Irsogladine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent D020011 - Protective Agents > D011837 - Radiation-Protective Agents D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D020011 - Protective Agents > D016588 - Anticarcinogenic Agents D000970 - Antineoplastic Agents Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. Target: PDE4; mACHR Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3\% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46\% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46\% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].
Irsogladine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent D020011 - Protective Agents > D011837 - Radiation-Protective Agents D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D020011 - Protective Agents > D016588 - Anticarcinogenic Agents D000970 - Antineoplastic Agents Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. Target: PDE4; mACHR Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3\% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46\% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46\% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].
1-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-yl)ethanone
PRP_M256
CONFIDENCE Transformation product, tentative ID (Level 2b); INTERNAL_ID 2404
anagrelide
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
Creatine phosphate disodium salt
Phosphocreatine disodium, one of organic compounds known as alpha amino acids and derivatives, is a substrate for the determination of creatine kinase and used to regenerate ATP during skeletal muscle contraction[1]. Phosphocreatine disodium, one of organic compounds known as alpha amino acids and derivatives, is a substrate for the determination of creatine kinase and used to regenerate ATP during skeletal muscle contraction[1].
3-[Cyano(2,4-Dichlorophenyl)Methylene]Carbazamidine
3,5,6-TRICHLORO-4-HYDRAZINO-PYRIDINE-2-CARBOXYLIC ACID
1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione
5-BROMO-BENZOOXAZOLE-2-CARBOXYLIC ACID METHYL ESTER
methyl 3-bromopyrazolo[1,5-a]pyrimidine-2-carboxylate
Methyl 6-chloro-3-(Methylthio)-1H-indole-5-carboxylate
[3-(4-bromophenyl)-4,5-dihydro-1,2-oxazol-5-yl]methanol
methyl 1-(5-bromopyridin-3-yl)cyclopropane-1-carboxylate
1-(7-BROMO-2H-BENZO[B][1,4]OXAZIN-4(3H)-YL)ETHANONE
2,6-DICHLORO-4-[(DIMETHYLAMINO)METHYL]PHENOL HYDROCHLORIDE
6-BROMO-BENZOOXAZOLE-2-CARBOXYLIC ACID METHYL ESTER
ETHYL 3-AMINO-4-CHLOROBENZO[B!THIOPHEN-2-CARBOXYLATE
6,7-DICHLORO-2-(TRIFLUOROMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINE
2-amino-2-(3,4-dichlorophenyl)acetic acid hydrochloride
4-Thiazoleacetic acid, 2-phenyl-, hydrochloride (1:1)
(R)-METHYL 1-(4-BROMOPHENYL)AZIRIDINE-2-CARBOXYLATE
1-[3-(2,4-DICHLOROPHENYL)ISOXAZOL-5-YL]ETHAN-1-ONE
Brofoxine
C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
1-Chloro-5-methoxy-4-nitro-2-(trifluoromethyl)benzene
6-BROMO-1,2,3,4-TETRAHYDRO-QUINOLINE-3-CARBOXYLIC ACID
Thiocyanic acid,2-(4-bromophenyl)-2-oxoethyl ester
3-Bromo-1-oxa-8-azaspiro[4.5]decane hydrochloride (1:1)
5-(3-bromophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
METHYL 3-BROMO-1H-PYRAZOLO[4,3-C]PYRIDINE-6-CARBOXYLATE
1-[3-(2,6-dichlorophenyl)-1,2-oxazol-5-yl]ethanone
2-AMINO-3-(5-CHLOROBENZOóB!THIOPHEN-3-YL)PROPANOIC ACID, TECH
4-CHLORO-2-METHOXY-6-(TRIFLUOROMETHYL)-3-PYRIDINEC
(2Z)-2-[Cyano(2,3-dichlorophenyl)methylene]hydrazinecarboximidamide
2-(4-CHLOROBENZENESULFONYL)-ETHYLAMINE HYDROCHLORIDE
2-(2,3-Dichlorophenyl)-2-guanidinyliminoacetonitrile
Methyl 7-chloro-8-fluoro-4-hydroxyquinoline-2-carboxylate
1-(6-bromo-5-hydroxy-2,3-dihydroindol-1-yl)ethanone
Disodium (1-methyl-4-oxoimidazolidin-2-ylidene)phosphoramidate
methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate
4,7-Dichloro-2-quinolinecarboxylic acid methyl ester
3-Bromo-1-methyl-5-(trifluoromethyl)pyridin-2(1H)-one
sodium,2-chloro-4-[(4-oxocyclohexa-2,5-dien-1-ylidene)amino]phenolate
1-[3-(3,4-DICHLOROPHENYL)ISOXAZOL-5-YL]ETHAN-1-ONE
3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBALDEHYDE
Tenonitrozole
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01A - Agents against amoebiasis and other protozoal diseases C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl chloride
3-(2-Chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid
6-phosphonato-2-dehydro-3-deoxy-D-galactate(3-)
An organophosphate oxoanion that is a trianion obtained via deprotonation of the carboxy and phosphate OH groups of 6-phospho-2-dehydro-3-deoxy-D-galactonic acid; major species at pH 7.3.
2-dehydro-3-deoxy-6-phosphonato-D-gluconate(3-)
An organophosphate oxoanion that is a trianion arising from deprotonation of the carboxylic acid and phosphate groups of 2-dehydro-3-deoxy-6-phospho-D-gluconic acid.
4-methylumbelliferone sulfate(1-)
An organosulfate oxoanion that is the conjugate base of 4-methylumbelliferone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.
